Welcome to the future of biopharmaceutical R&D and Manufacturing. Our advanced metabolic-strain engineering and purification platforms enable revolutionary efficiencies in biopharmaceutical discovery and manufacturing.
Accelerate the drug discovery process using AbSci’s all-in-one protein expression platform, SoluPro™. The optimization process enables rapid expression of soluble, complex proteins in high yields, and puts the focus on screening lead candidates instead of producing them.
SoluPro™, AbSci’s next-generation E. coli expression platform, generates diverse protein products at unparalleled yields compared to current manufacturing processes. Our technologies decrease COGs, reduce production times, and significantly increase plant capacity.
Traditionally, protein expression in E. coli is achieved either through cytoplasmic production as inclusion bodies or through secretion into the periplasmic space. SoluPro™ expresses soluble, disulfide linked proteins through production in a semi-oxidized cytoplasm.
SoluPro’s™ precisely tunable dual inducer system achieves peak production using straightforward induction titrations. Below is an example of Fab expression.
SoluPro™ speeds the time it takes to get new medicines to market by accelerating, or in some cases, cutting out steps entirely from the drug discovery and clinical development process. During development, SoluPro™ can produce gram quantities of material for preliminary screenings in a matter of days instead of weeks. In addition, because SoluPro™ has a demonstrated track record expressing difficult proteins and achieves higher protein production levels than mammalian systems, scientists can now access previously elusive and untestable therapeutic proteins. Once therapeutic candidates have been identified, the platform scales seamlessly for commercial production, therefore eliminating the 6-12 month cell-line development process.
At scale, SoluPro™ creates breakthrough efficiencies in biomanufacturing, eliminating the need for large plant build-outs and reducing drug substance costs by 50-75% for high-volume medicines such as insulin. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.
Absci collaborates with leading pharmaceutical companies to enable step-changes in productivity to their bio-pharmaceutical R&D and manufacturing.
AbSci is supported by a syndicate of experienced investors:
“AbSci reminds me of Genentech in the early 80’s, they’ve taken on some really hard problems to explain and there’s no fear around solving these key industry issues.”
V. Bryan Lawlis, PhD, Former VP of Process Science at Genentech
Join the Team | Change an Industry
At AbSci, we defy established protein expression conventions and continually invent new technologies and approaches which introduce efficiencies and cost savings to the biotech industry. We are looking for original thinkers, accomplished and energetic scientists who have the imagination to join us and re-define what’s possible.
NEWS / UPDATES / PRESS